{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-26-000068","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2026-08-07T11:00:11+00:00","discovered_at":"2026-08-07T11:05:00.452806+00:00","generated_at":"2026-08-07T11:05:51.424820+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ANI Pharma Q2 revenue $266M (+25.9%), GAAP EPS $1.05, adjusted EPS $2.21","bullets":["Q2 net revenue $266.0M, +25.9% YoY; GAAP net income $24.7M ($1.05/diluted) vs $8.1M prior year.","Cortrophin Gel revenue $117.1M, +43.5% YoY; ILUVIEN down 16.1% to $18.7M on shipment timing.","Adjusted non-GAAP EBITDA $71.6M (+32.4%); adjusted diluted EPS $2.21 vs $1.80 prior.","FY26 total revenue guidance reaffirmed $1,080-1,140M; Cortrophin Gel guidance narrowed to $520-540M from $540-575M.","Board authorized $100M share repurchase program through May 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-26-000068","json":"https://secwatch.observer/filing/0001023024-26-000068.json","markdown":"https://secwatch.observer/filing/0001023024-26-000068.md","text":"https://secwatch.observer/filing/0001023024-26-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/0001023024-26-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/ani-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T11:05:51.424820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}